New obesity drug shows promise in reducing belly fat
NCT ID NCT06824051
First seen Jan 22, 2026 · Last updated Jun 12, 2026 · Updated 30 times
Summary
This study tested the drug orforglipron in 120 adults with obesity or overweight (but not diabetes) to see how it changes body fat compared to a placebo. Participants were followed for about 8 months. The main goal was to measure changes in visceral fat, the deep belly fat linked to health risks. This is an early-phase study, so results help guide future research rather than provide a treatment now.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Axis
Dilworth, Minnesota, 56529, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Ohio Clinical Trials
Columbus, Ohio, 43212, United States
Conditions
Explore the condition pages connected to this study.